Dose response evaluation of resveratrol supplementation on cerebrovascular function, mood and cognitive performance in type 2 diabetes mellitus (T2DM).
- Conditions
- DiabetesMetabolic and Endocrine - DiabetesMental Health - Studies of normal psychology, cognitive function and behaviour
- Registration Number
- ACTRN12614000891628
- Lead Sponsor
- Dementia Collaborative Research Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
Non-insulin-dependent type 2 diabetes mellitus adults; non-smoking; women must be postmenopausal; dementia-free, Clinic SBP between 130-160mmHg ; BMI less than 40kg/m2; computer literate; have measurable ultrasound signal on both sides of the head; unlikely to change medication/supplements during the intervention.
Suspected dementia (3MS score of less than 78/100 determined at screening); Smokers or currently on nicotine therapy; Neurological conditions; Kidney/liver disease; Insulin therapy ; Major depression as diagnosed by a health care professional; Visual problems including the inability to distinguish the colours of red, green, blue and yellow; Illiterate; Physical difficulty in both hands that will impede on motor performance of the hand/arm; Unable to obtain a measurable signal in the MCA; Unwilling to provide two blood samples at each visit; Unwilling to maintain pre-enrolment physical activity levels and dietary habits for the duration of the trial.; Unwilling to fast for 4hr; Currently consuming resveratrol or other grape extract supplements.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method se of Transcranial Doppler (TCD) ultrasound to determine the most efficacious dose of resveratrol to improve cerebral vasodilator responsiveness (CVR) to hypercapnia in the anterior circulation (MCA) in adults with T2DM.[Weeks 1 to 4.]
- Secondary Outcome Measures
Name Time Method